Dalton Pharma Services Completes PAI Inspection

The U.S. FDA completed a PAI inspection of Dalton Pharma Services’ Health-Canada licensed manufacturing facility in Canada, in January 2019. This inspection paves way for Dalton to manufacture commercial API products for U.S. distribution.

The entire facility and the quality systems used for the manufacture and release of APIs were subject to a detailed compliance inspection by the FDA.  No FDA 483 inspectional observations were issued. This inspection means that the company has successfully demonstrated these activities are in compliance with the high standards of the Food and Drugs Act and its associated regulations.

Natalie Lazarowych, director of Quality, said, "This successful inspection is a critical breakthrough for Dalton as it is the first ever PAI at our facility. The successful FDA inspection with no 483s demonstrates our commitment to meeting all applicable regulatory standards for commercial manufacture, packaging and testing."

"I am proud of my team and their efforts in accomplishing this organizational milestone. Our hardworking, dedicated and exceptional employees are our greatest asset. This successful inspection exemplifies Dalton’s commitment to being a compliant cGMP API manufacturer for all our client`s drug candidates," said Peter Pekos, chief executive officer.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.